|
Serrano-Diaz L, Iniesta-Navalon C, Gomez-Espin R, Nicolas-de Prado I, Bernal-Morell E, Rentero-Redondo L. Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach. Rev Esp Enferm Dig. 2023 Aug;115(8):435-443. doi: 10.17235/reed.2022.8781/2022. PubMed PMID: 36562529.
AÑO: 2023; IF: 2.7
|
36562529
|
Bernal E, Garcia-Villalba E, Pons E, Hernandez MD, Baguena C, Puche G, Carter P, Martinez M, Alcaraz A, Tomas C, Munoz A, Vicente MR, Nunez ML, Sancho N, Villalba MC, Cano A, Minguela A. Remdesivir plus dexamethasone is associated to improvement in the clinical outcome of COVID-19 hospitalized patients regardless of their vaccination status. Med Clin (Barc). 2023 Aug 25;161(4):139-146. doi: 10.1016/j.medcli.2023.03.025. Epub 2023 Apr 5. PubMed PMID: 37100681; PubMed Central PMCID: PMC10073576.
AÑO: 2023; IF: 2.6
|
|
Del Pozo-Valero M, Corton M, Lopez-Rodriguez R, Mahillo-Fernandez I, Ruiz-Hornillos J, Minguez P, Villaverde C, Perez-Tomas ME, Barreda-Sanchez M, Mancebo E; STOP_Coronavirus Study Group; Paz-Artal E, Guillen-Navarro E, Almoguera B, Ayuso C. Age-dependent association of clonal hematopoiesis with COVID-19 mortality in patients over 60 years. Geroscience. 2023 Feb;45(1):543-553. doi: 10.1007/s11357-022-00666-5. Epub 2022 Oct 3. PubMed PMID: 36184726; PubMed Central PMCID: PMC9527133.
AÑO: 2023; IF: 5.3
|
|
Alonso-Navarro R, Ramirez M, Masia M, Paredes R, Montejano R, Povar-Echeverria M, Carratala J, Salavert M, Bernal E, Duenas C, Flores J, Fanjul F, Gutierrez I, Rico V, Mateu L, Cadinanos J, Berenguer J, Soriano A. Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses. BMC Infect Dis. 2023 May 4;23(1):286. doi: 10.1186/s12879-023-08222-y. PubMed PMID: 37142994; PubMed Central PMCID: PMC10157565.
AÑO: 2023; IF: 3.4
|
|
Santos JR, Domingo P, Portilla J, Gutierrez F, Imaz A, Vilchez H, Curran A, Valcarce-Pardeiro N, Payeras A, Bernal E, Montero-Alonso M, Yzusqui M, Clotet B, Videla S, Molto J, Paredes R. A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes. Open Forum Infect Dis. 2023 Oct 31;10(11):ofad542. doi: 10.1093/ofid/ofad542. eCollection 2023 Nov. PubMed PMID: 38023553; PubMed Central PMCID: PMC10661076.
AÑO: 2023; IF: 3.8
|